News

HBV education led by healthcare providers, decentralized testing, and strategies with more framework-driven mechanisms had the greatest impact on testing uptake.

The FDA approves Cobenfy, the first pharmacological approach to treating schizophrenia since the 1970s.

Elias discusses the challenges of prosthetic valve evaluation, highlighting the role of sonographers, Doppler imaging, and the importance of ongoing training.

This interview with Alexis features his reaction to the approval of lebrikizumab for eczema and its significance.

A randomized trial suggests gefarnate significantly reduces triglycerides and LDL-C in older adults on statins with residual hypertriglyceridemia.

Lack of retinopathy, lower hemoglobin A1c levels, preserved eGFR, microalbuminuria, and lower UPCR were linked to non-DKD.

The DELTA trial results on delgocitinib cream as a topical option for CHE were presented at the EADV Congress 2024.

Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial.

Rates of absolute and functional iron deficiency were high among adults in the US, even in those without anemia, heart failure, or chronic kidney disease.

Physicians who received pharmaceutical industry payments related to 4 different direct-acting antivirals were more likely to prescribe these medications.

These new findings were released by Eli Lilly and presented at the European Academy of Dermatology & Venereology Congress.

Leveraging deceased donor kidney transplantation data, study results suggest DCD-V kidney transplantation has similar short- and long-term outcomes versus DCD-III and DBD.

The joint guidelines address evidence on the management of patients before, during, and after noncardiac surgery since the last update in 2014.

These new findings were released by Arcutis Biotherapeutics and presented at the European Academy of Dermatology & Venereology Congress.

Announced on September 24, 2024, the approval marks the second treatment approved by the FDA for Niemann-Pick disease type C within one week.

These data suggest that the use of narrowband UVB phototherapy at home among patients with guttate or plaque psoriasis may function as a slightly less costly alternative to in-office use.

A Q&A with Nihar Desai, MD, on the PROMPT-Lipid trial and the potential of advancing technology for improving patient care in pragmatic ways.

Benjamin Scirica, MD, discusses the importance of team-based care and leveraging technology to optimize the management of cardiovascular risk factors.

Findings from the prospective cohort study suggest the value of serum Z polymer levels as a non-invasive disease-specific biomarker in patients with homozygous ZZ AATD liver disease.

Adding semaglutide to standard hidradenitis suppurative therapies achieved improvements in quality of life and fewer disease-related flares.

HCPLive spoke to Johnson on how strategies for addressing patient misconceptions about cholesterol management.

The ESS device, leveraging artificial intelligence, may allow for enhanced decision making among nurse practitioners as well as physician assistants evaluating patients for skin cancer.

Nihar Desai, MD, discusses the results of the PROMPT-Lipid trial while on-site at the 2024 Family Heart Global Summit.

Laurence Sperling, MD, discusses his presentation from the 2024 Family Heart Global Summit examining public health efforts for prevention of cardiovascular disease.

Magnetic resonance elastography and transient elastography did not accurately predict high-grade fibrosis on liver biopsy in children with MASLD.

At the Family Heart Summit, Nihar Desai, MD, discussed using EMR alerts to improve lipid therapy for high-risk ASCVD, as shown in the PROMPT-Lipid trial.

These data from the DISCREET study highlight the impact of apremilast on men and women with genital psoriasis.

The FDA has set a PDUFA target action date of May 22, 2025, for roflumilast foam 0.3% for individuals aged ≥12 with scalp and body psoriasis.